RecruitingNCT06250842

Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study

Assessing the Cognitive Effects of Chronic Benzodiazepine Use in Patients: A Comprehensive Study Using fNIRs and PET/MRI Technologies


Sponsor

The First Affiliated Hospital of Dalian Medical University

Enrollment

100 participants

Start Date

Feb 11, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced brain imaging (fNIRS and PET/MRI) to examine how long-term use of benzodiazepines (anti-anxiety or sleep medications like diazepam or lorazepam) affects brain function and insulin action in the brain, which may be related to memory and cognitive problems. **You may be eligible if...** - You have been taking benzodiazepines continuously for at least 3 months (or you are a matched non-user participating as a control) - You have at least 6 years of education - You abstained from alcohol, coffee, and psychoactive substances in the 24 hours before the exam **You may NOT be eligible if...** - You have brain damage from any cause (trauma, dementia, epilepsy, tumors) - You have severe systemic diseases such as cancer - You had a stroke or cerebrovascular event in the past 3 months - You have a history of substance abuse (alcohol, opioids) beyond benzodiazepines - You are unable to cooperate with brain imaging or assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06250842


Related Trials